股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 巨子生物控股有限公司 呈交日期: 2025年12月3日 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | ...

每经AI快讯，巨子生物(02367.HK)昨日受回购消息刺激一度涨逾12%，今日股价回落逾4%，截至发稿 跌3.38%，报38.36港元，成交额4.28亿港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - The stock of Giant Bio (02367) experienced a significant increase of over 12% following a share buyback announcement, but subsequently fell by over 4% [1] Group 1: Share Buyback Announcement - Giant Bio announced plans to exercise its share buyback authorization, allowing the company to repurchase up to 103.6 million shares, which represents 10% of its issued shares excluding treasury shares [1] Group 2: Sales Performance - According to a report from Bank of America Securities, sales for the Co-Beauty brand during the Double Eleven shopping festival were under pressure, with sales on Tmall and Douyin declining by 20% and 50% year-on-year, respectively [1] - In contrast, the Co-Li Jin brand achieved positive growth during the same period [1] Group 3: Earnings Guidance - Management has revised down its earnings guidance for the year, expecting revenue to remain flat or slightly decline year-on-year, and has lowered its net profit forecast to a mid-to-high single-digit percentage decline year-on-year [1]

Core Viewpoint - The stock of Giant Bio (02367) experienced a significant increase of over 12% due to a share buyback announcement, but subsequently fell by over 4% [1] Group 1: Share Buyback Announcement - Giant Bio announced plans to exercise its share buyback authorization, allowing the company to repurchase up to 103.6 million shares, which represents 10% of the issued shares excluding treasury shares [1] Group 2: Sales Performance - According to a report from Bank of America Securities, sales for the Co-Beauty brand during the Double Eleven shopping festival were under pressure, with sales on Tmall and Douyin declining by 20% and 50% year-on-year, respectively [1] - In contrast, the Co-Li Jin brand achieved positive growth during the same period [1] Group 3: Earnings Guidance - Management has revised down the earnings guidance for the year, expecting revenue to remain flat or slightly decline year-on-year, and has lowered the net profit forecast to a year-on-year decline in the mid to high single digits [1]

Core Viewpoint - Bank of America Securities has downgraded the revenue forecasts for Giant Bio (02367) for 2025 to 2027 by 21%, 24%, and 25% respectively, and has also reduced net profit forecasts by 21%, 24%, and 24% respectively, while lowering the target price from HKD 68.3 to HKD 55.5, but maintains a "Buy" rating due to the potential of newly approved injectable aesthetic products to drive growth next year [1] Revenue and Profit Forecasts - Revenue forecasts for Giant Bio have been reduced by 21%, 24%, and 25% for the years 2025, 2026, and 2027 respectively [1] - Net profit forecasts have also been adjusted downwards by 21%, 24%, and 24% for the same years [1] Target Price Adjustment - The target price for Giant Bio has been decreased from HKD 68.3 to HKD 55.5 [1] Sales Performance - During the Double Eleven shopping festival, sales for the Comfy brand were under pressure, with a year-on-year decline of 20% on Tmall and 50% on Douyin [1] - In contrast, the Collgene brand achieved positive growth during the same period [1] Management Guidance - Management has lowered the performance guidance for the current year, expecting revenue to be flat or slightly down year-on-year [1] - The net profit forecast has been adjusted to reflect a year-on-year decline in the mid to high single digits [1]

Core Viewpoint - Bank of America Securities has downgraded the revenue forecasts for Giant Bio (02367) for 2025 to 2027 by 21%, 24%, and 25% respectively, and has also reduced net profit forecasts by 21%, 24%, and 24%. The target price has been lowered from HKD 68.3 to HKD 55.5, but the "Buy" rating is maintained due to expectations that newly approved injectable aesthetic products will drive growth next year [1] Group 1 - Giant Bio's sales during the Double Eleven shopping festival were under pressure, with management reporting a year-on-year sales decline of 20% on Tmall and 50% on Douyin for the Comfy brand [1] - In contrast, the Collgene brand achieved positive growth during the same period [1] - Management has lowered the performance guidance for this year, expecting revenue to be flat or slightly down year-on-year, and has adjusted net profit forecasts to reflect a mid to high single-digit decline [1]

Core Viewpoint - CICC has downgraded the net profit forecast for Giant Bio (02367) for 2025-2026 by 25% and 33% to 1.91 billion and 2.14 billion yuan respectively, citing short-term pressure on cosmetics sales. The current stock price corresponds to a P/E ratio of 20x for 2025 and 18x for 2026. The target price has been reduced by 20% to 56 HKD, which implies a potential upside of 41% based on the adjusted earnings forecast [1]. Company Current Situation - On December 2, the company announced a plan to repurchase up to 104 million shares, accounting for 10% of the issued shares, and is communicating its strategic plans for 2026 regarding product matrix expansion, brand operation, and channel development. This repurchase reflects management's confidence, and the company’s R&D capabilities, brand recognition, and team cohesion remain strong, suggesting potential operational improvements through optimized product structure and timely operational adjustments [2][3]. Product and Channel Expansion Plans - The company has a rich reserve of new products for 2026, with plans to launch four key new products in the collagen repair series and expand channel coverage for existing brands. The company aims to strengthen its online presence and expand offline channels, including clinics and self-operated stores, with successful initial steps in Southeast Asia. The contribution from second-tier products is expected to increase, driving healthy growth in the cosmetics business [4]. Medical Aesthetics Growth - The medical aesthetics team is expanding, with strong experience in developing star products and commercial preparations progressing smoothly. The company’s R&D strength, brand recognition, and team cohesion are expected to support long-term growth, especially as the cosmetics market recovers and the medical aesthetics segment contributes additional growth [5].

Core Viewpoint - CICC has downgraded the profit forecast for Giant Bio (02367) for 2025-2026 by 25% and 33% to 1.91 billion and 2.14 billion yuan respectively, reflecting short-term pressure on cosmetics sales. The current stock price corresponds to a P/E of 20x for 2025 and 18x for 2026. The target price has been reduced by 20% to 56 HKD, indicating a potential upside of 41% based on the adjusted profit forecast [1]. Company Current Situation - On December 2, the company announced a plan to repurchase up to 104 million shares, accounting for 10% of the issued shares, and communicated its strategic plans for 2026 regarding product matrix expansion, brand operation, and channel development. This repurchase reflects management's confidence, and the company is expected to improve operations through optimized product structure and timely operational adjustments [2][3]. Share Repurchase Plan - The company plans to use its own funds to repurchase up to 104 million shares, which may be canceled or held as treasury stock. This repurchase plan is seen as a demonstration of management's long-term confidence in the company's growth and is expected to enhance earnings per share and shareholder returns [3]. Product Matrix and Channel Expansion Planning - For 2026, the company has a rich reserve of new products, including four key new products from the core collagen stick marketing and pricing strategy. Additionally, the company plans to upgrade its product lines and expand channel coverage, including online influencer marketing and offline distribution channels. The second-tier products are expected to contribute to healthy growth in the cosmetics business [4]. Medical Aesthetics Second Curve Progress - The company's medical aesthetics team is expanding, with successful commercialization preparations based on previous experience in developing star products. The company maintains strong R&D capabilities, brand recognition, and team cohesion, suggesting a broad growth space as the cosmetics market recovers and the medical aesthetics segment contributes additional revenue [5].

Core Insights - On December 2, 2023, Juzibio made its debut on the Hong Kong Stock Connect active trading list for the first time in a month, with a trading volume of 9.17 billion HKD and a net buy of 1.32 billion HKD, closing up 8.53% [1][2] Trading Activity Summary - The total trading volume for active stocks on the Hong Kong Stock Connect on December 2 was 292.74 billion HKD, accounting for 37.92% of the day's total trading amount, with a net buying amount of 16.86 billion HKD [1] - Alibaba-W led the trading volume with 83.40 billion HKD, followed by Xiaomi Group-W at 38.44 billion HKD and Meituan-W at 36.15 billion HKD [1][2] - The most frequently listed stocks in the past month were Alibaba-W and Tencent Holdings, each appearing 22 times, indicating strong interest from Hong Kong Stock Connect investors [1]

12月2日港股通成交活跃股 | 代码 | 简称 | 类型 | 成交金额（万港元） | 成交净买入（万港元） | 日涨跌幅（%） | | --- | --- | --- | --- | --- | --- | | 09988 | 阿里巴巴-W | 港股通(沪) | 512623.30 | 36697.46 | 1.36 | | 09988 | 阿里巴巴-W | 港股通(深) | 321347.00 | -995.27 | 1.36 | | 03690 | 美团-W | 港股通(沪) | 249509.11 | 17125.97 | -3.06 | | 00700 | 腾讯控股 | 港股通(沪) | 212952.76 | -68401.90 | -0.40 | | 01810 | 小米集团-W | 港股通(深) | 208598.00 | 42111.80 | 0.99 | | 01810 | 小米集团-W | 港股通(沪) | 175816.18 | -4105.95 | 0.99 | | 00763 | 中兴通讯 | 港股通(沪) | 148079.84 | 9383.77 | -5.64 | | 0070 ...